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sources. Direct costs of diabetes complications and drug treat-
ment were projected over patients’ lifetimes from a UK National
Health Service perspective. Both costs and QALYs were dis-
counted at 3.5% p.a. Sensitivity analyses were performed.
RESULTS: The model projected that treatment with IAsp would
result in an additional 0.08 LYG and 0.09 QALYs per patient.
Total lifetime costs/patient were estimated to increase by £419.
The cost/LYG was calculated to be £5430 and cost/QALY
£4825. CONCLUSION: The model predicted that treatment
with insulin aspart would result in long-term improvements in
health outcomes and quality of life compared to soluble human
insulin in patients with type-1 diabetes. The cost-effectiveness
result is well within the range considered to represent good value
for money in the UK.
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OBJECTIVE: In their evaluation of the cost effectiveness of
insulin glargine, NICE included an assumption that switching to
insulin would result in decreased health utility (8%). This altered
notably any resulting cost-utility ratios. The purpose of this
study was to test this hypothesis. METHODS: The design was
a before-and-after study for type-2 patients who required switch-
ing to insulin. All followed an algorithm to achieve fasting and
post-prandial blood glucose targets. Outcome measures included
a measure of utilit (EQ5Dindex) at baseline, three-months and six-
months. This report was a preliminary analysis of the ﬁrst 48
subjects, of which 32 had completed 12 weeks and 26 had com-
pleted the full 24-week study. RESULTS: Of the 26 subjects, 21
(81%) remained on glargine with or without OHAs, two
required additional pre-meal boluses, and three required twice-
daily pre-mixtures. The mean (SD) EQ5Dindex at baseline was
0.655 (0.275; n = 24), at three-months 0.637 (0.333; D vs. base-
line NS) and at six-months 0.710 (0.319; D vs. baseline NS). At
three-months, six patients had worse utility and six better utility,
while 12 reported no change. At six-months, four patients had
worse utility after switching, and 11 had better utility, the
remaining nine subjects reported no change. Over the six-
months, mean BMI increased from 29.4 to 30.0kg/m2 (n = 23,
p < 0.001) and mean HbA1c decreased from 10.1% to 7.8% (n
= 23, p < 0.001). Mean daily insulin dose at six-months was 61.6
units (range 24 to 178). CONCLUSIONS: This is a limited but
important interim analysis. The hypothesis that switching to
insulin–here insulin glargine—resulted in a notable decrease in
utility (quality of life) was rejected, with a trend for a clinically
meaningful improvement in utility. Economic evaluations
should, therefore, exclude this assumption. This observation is
not necessarily generalisable to all insulin regimens.
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OBJECTIVES: To evaluate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in
patients with type-2 diabetes. METHODS: Retrospective analy-
sis of a state Medicaid claims data was conducted in patients
with type-2 diabetes identiﬁed using ICD-9 diagnosis codes
(250.0¥–250.9¥, where x = 0 or two) in the year 2001. Patients
≥65 years or those with managed care coverage were excluded.
Presence of cardiovascular co-morbidity in the year 2001 was
identiﬁed using appropriate ICD-9 codes. Semi-logarithmic OLS
models were used to estimate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in year
2002, controlling for demographic characteristics (age, gender,
race, and urban/rural location), presence of peripheral vascular
conditions, cerebrovascular conditions, hypertension, hyperlipi-
demia, and other co-morbid conditions. Two-part models were
used for estimating the impact of cardiovascular co-morbidity on
speciﬁc costs such as ER/hospitalization, outpatient and pre-
scription. Smearing estimates were used to interpret the results
from the semi-logarithmic models. RESULTS: Presence of car-
diovascular co-morbidity had a signiﬁcant impact on all cate-
gories of total and diabetes-related health care costs, except
diabetes-related prescription drug costs. Type-2 diabetes patients
with cardiovascular co-morbidity had signiﬁcantly higher 
total health care costs (38.9%, $12,550 vs. $9,031), ER/
hospitalization costs (239.8%, $4,845 vs. $1,426), outpatient
costs (35.3%, $3,956 vs. $2,925) and prescription drug costs
(15.1%, $4,686 vs. $4,071) compared to those without cardio-
vascular co-morbidity. Similarly, type-2 diabetes patients with
cardiovascular co-morbidity had signiﬁcantly higher diabetes-
related total health care costs (59.7%, $4349 vs. $2724),
ER/hospitalization costs (346.8%, $1911 vs. $428) and outpa-
tient costs (17.4%, $740 vs. $631) compared to patients without
cardiovascular co-morbidity. CONCLUSIONS: Presence of car-
diovascular co-morbidity in patients with type-2 diabetes signif-
icantly increases total and diabetes-related health care costs, with
ER/hospitalization costs accounting for the highest percentage
increase.
PDB25
DEPRESSION IN PATIENTS WITH TYPE-2 DIABETES: IMPACT
ON UTILIZATION PATTERNS AND ADHERENCE TO ORAL
HYPOGLYCEMIC AGENTS
Kalsekar I1, Madhavan SM2,Amonkar M3, Douglas S2, Makela E2,
Scott V2
1Butler University, Indianapolis, IN, USA; 2West Virginia University,
Morgantown, WV, USA; 3GlaxoSmithKline, Collegeville, PA, USA
OBJECTIVE: To examine the impact of pre-existing depression
on utilization patterns and adherence to oral hypoglycemic
agents (OHAs) in patients newly diagnosed with type-2 diabetes.
METHODS: Newly diagnosed type-2 diabetes patients during
the three-year period (1998–2000) were identiﬁed from a Med-
icaid claims database. Presence of pre-existing depression was
determined on the basis of ICD-9 CM codes for depression. 
Utilization patterns (switching, augmentation) and adherence to
OHAs were computed for a 12-month follow up period from the
date of the index OHA prescription. A multivariate framework
was used to estimate the impact of depression on utilization pat-
terns and adherence, controlling for confounders such as demo-
graphics, co-morbidity, diabetes severity, regimen complexity,
and interaction with health care providers. RESULTS: A total of
1326 newly diagnosed type-2 diabetes patients were identiﬁed
(depressed = 471; non-depressed = 855). A signiﬁcantly higher
number of depressed patients (23.3%) switched or augmented
therapy as compared to non-depressed patients (16.2%). Results
of a multinomial logit model indicated that controlling for
covariates, patients with depression were 1.7 times more likely
to switch (p = 0.046) and two times more likely to augment
